Multinational pharmaceutical companies post mixed results
By Son, Hyung-Min | translator Alice Kang
24.04.16 12:10:53
가나다라
0
Pfizer and Gilead sales drop sharply...impacted by the sharp fall in sales of their COVID-19 vaccines and treatments
GSK’s sales rise 40% supported by the growth of Shingrix’s sales…Sanofi and Amgen’s sales are also on the rise
The Korean subsidiaries of multinational pharmaceutical companies posted mixed performances last year. Sales of Pfizer Korea, MSD Korea, and Gilead Sciences Korea, which developed COVID-19 vaccines and treatments, plummeted due to the base effect of the pandemic. On the other hand, GlaxoSmithKline (GSK) and Amgen Korea saw sales increase thanks to the growth in sales of their innovative new drugs.
According to the Financial Supervisory Service on Saturday, the sales of 36 major multinational pharmaceutical companies in Korea fell 12.5% to KRW 10.37 trillion last year from KRW 11.84 trillion in 2022.
Of the 36 MNCs, 12 companies, including Pfizer, MSD, Janssen, Gilead, Bayer, Alcon, Lilly, M
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)